A prospective phase II study of carboplatin and nab-paclitaxel in patients with advanced non-small cell lung cancer and concomitant interstitial lung disease (HOT1302)

被引：33

作者：

Asahina, Hajime ^{[1
,2
]}

Oizumi, Satoshi ^{[1
,2
,3
]}

Takamura, Kei ^{[4
]}

Harada, Toshiyuki ^{[5
]}

Harada, Masao ^{[3
]}

Yokouchi, Hiroshi ^{[3
,6
]}

Kanazawa, Kenya ^{[6
]}

Fujita, Yuka ^{[7
]}

Kojima, Tetsuya ^{[8
]}

Sugaya, Fumiko ^{[9
]}

Tanaka, Hisashi ^{[10
]}

Honda, Ryoichi ^{[11
]}

Kikuchi, Eiki ^{[1
,2
]}

Ikari, Tomoo ^{[1
,2
,5
]}

Ogi, Takahiro ^{[4
,8
]}

Shimizu, Kaoruko ^{[1
,2
]}

Suzuki, Masaru ^{[1
,2
]}

Konno, Satoshi ^{[1
,2
]}

Dosaka-Akita, Hirotoshi ^{[2
,12
]}

Isobe, Hiroshi ^{[8
]}

Nishimura, Masaharu ^{[1
,2
]}

机构：

[1] Hokkaido Univ, Fac Med, Dept Resp Med, Sapporo, Hokkaido, Japan

[2] Hokkaido Univ, Grad Sch Med, Sapporo, Hokkaido, Japan

[3] Natl Hosp Org Hokkaido Canc Ctr, Dept Resp Med, Sapporo, Hokkaido, Japan

[4] Obihiro Kosei Gen Hosp, Dept Resp Med, Obihiro, Hokkaido, Japan

[5] JCHO Hokkaido Hosp, Ctr Resp Dis, Sapporo, Hokkaido, Japan

[6] Fukushima Med Univ, Sch Med, Dept Pulm Med, Fukushima, Japan

[7] Natl Hosp Org Asahikawa Med Ctr, Dept Resp Med, Asahikawa, Hokkaido, Japan

[8] KKR Sapporo Med Ctr, Dept Med Oncol, Sapporo, Hokkaido, Japan

[9] Teine Keijinkai Hosp, Dept Resp Med, Sapporo, Hokkaido, Japan

[10] Hirosaki Univ, Dept Resp Med, Grad Sch Med, Hirosaki, Aomori, Japan

[11] Asahi Chuo Hosp, Dept Resp Med, Asahi, Japan

[12] Hokkaido Univ, Fac Med, Dept Med Oncol, Sapporo, Hokkaido, Japan

来源：

LUNG CANCER | 2019年 / 138卷

关键词：

Non-small cell lung cancer; Interstitial lung disease; Carboplatin; Nab-paclitaxel; Clinical trial; ALBUMIN-BOUND PACLITAXEL; SOLVENT-BASED PACLITAXEL; 1ST-LINE THERAPY; ACUTE EXACERBATION; PLUS CARBOPLATIN; CHEMOTHERAPY; EFFICACY; SAFETY; COMBINATION; RISK;

D O I：

10.1016/j.lungcan.2019.09.020

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Objectives: Patients with concomitant advanced non-small cell lung cancer (NSCLC) and interstitial lung disease (ILD) are excluded from most clinical chemotherapy trials because of the high risk of exacerbating the latter condition. This study prospectively investigated the efficacy and safety of albumin-bound paclitaxel (nab-paclitaxel) in combination with carboplatin in patients with both advanced NSCLC and ILD. Patients and methods: The enrolled patients had treatment-naive, advanced NSCLC with ILD. Patients received 100 mg/m(2) nab-paclitaxel weekly and carboplatin at an area under the concentration-time curve of 6 once every 3 weeks for 4-6 cycles. The primary endpoint was the overall response rate (ORR); secondary endpoints included toxicity, progression-free survival (PFS), and overall survival (OS). Results: Thirty-six patients were enrolled between April 2014 and September 2017. Sixteen patients (44.4%) had adenocarcinoma, 15 (41.7%) had squamous cell carcinoma (Sq), and 5 (13.9%) had non-small cell carcinoma. The median number of cycles administered were 4 (range: 1-6). The ORR was 55.6% (95% confidence interval [CI]: 39.6-70.5). The median PFS and OS were 5.3 months (95% CI: 3.9-8.2) and 15.4 months (95% CI: 9.4-18.7), respectively. A greater proportion of patients with Sq experienced improvements than did those with non-Sq: ORRs, 66.7% (95% CI: 41.7-84.8) vs. 47.6% (95% CI: 28.3-67.6) (P = 0.254); median PFS, 8.2 months (95% CI: 4.0-10.2) vs. 4.1 months (95% CI: 3.3-5.4) (HR, 0.60 [95% CI, 0.30-1.20]; P = 0.15); and median OS, 16.8 months (95% CI: 9.8 not reached) vs. 11.9 months (95% CI: 7.3-17.4) (HR, 0.56 [95% CI, 0.24-1.28]; P = 0.17). Two patients (5.6%) experienced grade >= 2 pneumonitis and 1 patient (2.8%) died. Conclusion: Weekly nab-paclitaxel combined with carboplatin showed favorable efficacy with acceptable toxicity in patients with both advanced NSCLC and ILD.

引用

页码：65 / 71

页数：7

共 40 条

[1]

Asahina H, 2012, ANN ONCOL, V23, P497

[2] Molecular biomarkers for lung adenocarcinoma [J].

Calvayrac, Olivier ;

Pradines, Anne ;

Pons, Elvire ;

Mazieres, Julien ;

Guibert, Nicolas .

EUROPEAN RESPIRATORY JOURNAL, 2017, 49 (04)

[3] Incidence of Acute Exacerbation of Interstitial Pneumonia in Operated Lung Cancer: Institutional Report and Review [J].

Chida, Masayuki ;

Kobayashi, Satoru ;

Karube, Yoko ;

Hayama, Makio ;

Tamura, Motohiko ;

Ishihama, Hiromi ;

Oyaizu, Takeshi .

ANNALS OF THORACIC AND CARDIOVASCULAR SURGERY, 2012, 18 (04) :314-317

[4] Acute exacerbations of idiopathic pulmonary fibrosis [J].

Collard, Harold R. ;

Moore, Bethany B. ;

Flaherty, Kevin R. ;

Brown, Kevin K. ;

Kaner, Robert J. ;

King, Talmadge E., Jr. ;

Lasky, Joseph A. ;

Loyd, James E. ;

Noth, Imre ;

Olman, Mitchell A. ;

Raghu, Ganesh ;

Roman, Jesse ;

Ryu, Jay H. ;

Zisman, David A. ;

Hunninghake, Gary W. ;

Colby, Thomas V. ;

Egan, Jim J. ;

Hansell, David M. ;

Johkoh, Takeshi ;

Kaminski, Naftali ;

Kim, Dong Soon ;

Kondoh, Yasuhiro ;

Lynch, David A. ;

Mueller-Quernheim, Joachim ;

Myers, Jeffrey L. ;

Nicholson, Andrew G. ;

Selman, Moises ;

Toews, Galen B. ;

Wells, Athol U. ;

Martinez, Fernando J. .

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2007, 176 (07) :636-643

[5] Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of Cremophor-free, albumin-bound paclitaxel, ABI-007, compared with Cremophor-based paclitaxel [J].

Desai, N ;

Trieu, V ;

Yao, ZW ;

Louie, L ;

Ci, S ;

Yang, A ;

Tao, CL ;

De, T ;

Beals, B ;

Dykes, D ;

Noker, P ;

Yao, R ;

Labao, E ;

Hawkins, M ;

Soon-Shiong, P .

CLINICAL CANCER RESEARCH, 2006, 12 (04) :1317-1324

[6] Nivolumab for advanced non-small cell lung cancer patients with mild idiopathic interstitial pneumonia: A multicenter, open-label single-arm phase II trial [J].

Fujimoto, Daichi ;

Yomota, Makiko ;

Sekine, Akimasa ;

Morita, Mitsunori ;

Morimoto, Takeshi ;

Hosomi, Yukio ;

Ogura, Takashi ;

Tomioka, Hiromi ;

Tomii, Keisuke .

LUNG CANCER, 2019, 134 :274-278

[7] Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer [J].

Gandhi, L. ;

Rodriguez-Abreu, D. ;

Gadgeel, S. ;

Esteban, E. ;

Felip, E. ;

De Angelis, F. ;

Domine, M. ;

Clingan, P. ;

Hochmair, M. J. ;

Powell, S. F. ;

Cheng, S. Y. -S. ;

Bischoff, H. G. ;

Peled, N. ;

Grossi, F. ;

Jennens, R. R. ;

Reck, M. ;

Hui, R. ;

Garon, E. B. ;

Boyer, M. ;

Rubio-Viqueira, B. ;

Novello, S. ;

Kurata, T. ;

Gray, J. E. ;

Vida, J. ;

Wei, Z. ;

Yang, J. ;

Raftopoulos, H. ;

Pietanza, M. C. ;

Garassino, M. C. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (22) :2078-2092

[8] Randomized crossover pharmacokinetic study of solvent-based paclitaxel and nab-paclitaxel [J].

Gardner, Erin R. ;

Dahut, William L. ;

Scripture, Charity D. ;

Jones, Jacquin ;

Aragon-Ching, Jeanny B. ;

Desai, Neil ;

Hawkins, Michael J. ;

Sparreboom, Alex ;

Figg, William D. .

CLINICAL CANCER RESEARCH, 2008, 14 (13) :4200-4205

[9] A multicenter, open-label, phase II trial of S-1 plus carboplatin in advanced non-small cell lung cancer patients with interstitial lung disease [J].

Hanibuchi, Masaki ;

Kakiuchi, Soji ;

Atagi, Shinji ;

Ogushi, Fumitaka ;

Shimizu, Eiji ;

Haku, Takashi ;

Toyoda, Yuko ;

Azuma, Masahiko ;

Kondo, Mayo ;

Kawano, Hiroshi ;

Otsuka, Kenji ;

Sakaguchi, Satoshi ;

Nokihara, Hiroshi ;

Goto, Hisatsugu ;

Nishioka, Yasuhiko .

LUNG CANCER, 2018, 125 :93-99

[10] Augmentation of the Enhanced Permeability and Retention Effect with Nitric Oxide-Generating Agents Improves the Therapeutic Effects of Nanomedicines [J].

Islam, Waliul ;

Fang, Jun ;

Imamura, Takahisa ;

Etrych, Tomas ;

Subr, Vladimir ;

Ulbrich, Karel ;

Maeda, Hiroshi .

MOLECULAR CANCER THERAPEUTICS, 2018, 17 (12) :2643-2653

← 1 2 3 4 →